Strategic report Corporate governance Financial statements Financial statements Notes to the consolidated financial statements continued 30.
Financial policies for risk management and their objectives continued 31.
Derivative financial instruments continued In December 2016, the Group entered arrangements designed to address the JPY exchange exposure for the upcoming year.
These Liquidity risk of assets liabilities forward contracts are designated as effective cash flow hedges and the movement in fair value in the year resulted in a loss of $nil, which Liquidity risk has been reflected in other comprehensive income.
These amounts are based on market values of equivalent instruments at the balance Less than one Two to five More than five sheet date.
year years years Total 2016 $m $m $m $m The Group believes that the effect on the value of cash flow hedges of currency fluctuations is not significant and will not materially affect Cash and cash equivalents 155 155 the financial position of the Group.
Trade receivables 699 699 Interest rate swaps Interest-bearing loans and borrowings 73 787 860 The Group uses interest rate swaps to manage its exposure to interest rate movements on its bank borrowings.
These contracts have Interest-bearing overdrafts 10 10 nominal values of $nil 2015: $4 million and have fixed interest payments at a rate of 4.34% 2015: 1.94% to 4.34% for periods up until Interest-bearing Import and Export loans 64 64 2017 and have floating interest receipts at EURIBOR.
Trade payables and accruals 329 329 378 787 409 The fair value of swaps entered by the Group is estimated as a liability of $nil 2015: liability of $nil.
These amounts are based on fair values provided by the banks that originated the swaps and are based on equivalent instruments at the balance sheet date.
The interest rate swaps that the Group was committed to at the year-end are held at fair value through profit and loss.
Less than one Two to five More than five year years years Total The Group believes that the effect on the value of interest rate swaps by interest rate fluctuations will not materially affect the financial 2015 $m $m $m $m position of the Group.
Cash and cash equivalents 553 553 Trade receivables 432 432 32.
Other non-current liabilities Interest-bearing loans and borrowings 72 666 5 743 As at 31 December Interest-bearing overdrafts 12 12 2016 2015 Interest-bearing Import and Export loans 59 59 $m $m Trade payables and accruals 261 261 Contingent consideration and liability note 43 226 581 666 5 90 Supply Manufacturing Agreement 33 Co-development and earnout payment 14 18 At 31 December 2016 the Group had undrawn facilities of $1,289 million 2015: $1,580 million.
Of these facilities, $1,093 million 2015: Others 4 2 $1,381 million was committed and the remainder was uncommitted.
277 20 Contingent consideration and liability: In respect to note 27, the non-current portion of the year-end balance is $146 million related to 31.
Derivative financial instruments the contingent consideration and another $80 million related to the opening balance sheet contingent liability.
Foreign exchange forward contracts The Group utilises currency derivatives to hedge significant future transactions and cash flows.
The Group uses foreign currency forward Supply Manufacturing Agreement: As part of the acquisition of West-Ward Columbus, the Group entered into supply and contracts in the management of its exchange rate exposures.
The instruments purchased are primarily denominated in the currencies of manufacturing contracts with Boehringer.
Co-development and earnout payment agreement: In respect to note 27, the non-current portion of the year-end balance is At the balance sheet date, the total notional amount of outstanding forward foreign exchange contracts that the Group was committed to $14 million.
have been translated at 31 December exchange rates as below: 2016 2015 33.
Share capital $m $m Issued and fully paid included in shareholders equity: Foreign exchange forward contracts JPY 6 2016 2015 Number m $m Number m $m At 1 January 200 35 199 35 Issued during the year ordinary shares of 10p each 41 5 1 At 31 December 241 40 200 35 34.
Non-controlling interests 2016 2015 $m $m At 1 January 15 19 Share of profit 3 2 Dividends paid 1 2 Currency translation loss 3 4 Acquisition of subsidiaries 1 At 31 December 15 15 Annual Report 2016 187 178 Hikma Pharmaceuticals plc Annual Report 2016 179
